Aquestive Therapeutics (AQST) Projected to Post Quarterly Earnings on Wednesday

Aquestive Therapeutics (NASDAQ:AQST) is anticipated to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Aquestive Therapeutics to announce earnings of ($0.10) per share and revenue of $11.02 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $11.42 million. On average, analysts expect Aquestive Therapeutics to post ($0.50) EPS for the current fiscal year and ($0.50) EPS for the next fiscal year.

Aquestive Therapeutics Trading Up 2.5%

Shares of AQST stock opened at $4.07 on Wednesday. The business’s 50 day moving average is $4.68 and its two-hundred day moving average is $4.21. Aquestive Therapeutics has a twelve month low of $2.93 and a twelve month high of $7.05.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AQST shares. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price objective on shares of Aquestive Therapeutics in a research note on Thursday, September 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $8.60.

Insider Buying and Selling

In other news, CEO Daniel Barber sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $4.22, for a total value of $105,500.00. Following the completion of the sale, the chief executive officer directly owned 627,317 shares of the company’s stock, valued at $2,647,277.74. This trade represents a 3.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of Aquestive Therapeutics stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the sale, the insider owned 235,689 shares in the company, valued at approximately $1,230,296.58. This trade represents a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 58,750 shares of company stock valued at $271,675. Company insiders own 6.81% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.